More da­ta, more dol­lars: Three biotechs post of­fer­ings af­ter tri­al read­outs

The pat­tern goes as fol­lows: roll out the da­ta first, and then go to in­vestors and ask for more mon­ey.

Three biotechs played right in­to that strat­e­gy on Tues­day.

The first was Jasper Ther­a­peu­tics, which kicked things off Tues­day af­ter­noon by an­nounc­ing it plans on sell­ing shares via a pub­lic of­fer­ing. Jasper elab­o­rat­ed Wednes­day morn­ing, dis­clos­ing it would sell 60 mil­lion shares of stock at $1.50 each, for around $90 mil­lion. The stock $JSPR ticked up more than 10% af­ter the open­ing bell.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER